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esis of tubular injury and interstitial fibrosis in experimentalInhibition of nuclear factor-B activation by pyrrolidine dithio-
FK506-induced chronic nephropathy.carbamate prevents chronic FK506 nephropathy.
Background. Chronic tacrolimus (FK506) nephrotoxicity is
characterized by renal fibrosis with interstitial inflammation.
Since nuclear factor-B (NF-B) plays a key role in chronic Tacrolimus (FK506) is a potent immunosuppressiveinflammatory diseases including renal disease, the present study
agent that is effective in allograft prophylaxis after organwas conducted to elucidate the role of NF-B in the pathogenesis
transplantation. However, its clinical use is limited byof chronic FK506-induced nephropathy.
Methods. FK506 (1 mg/kg/day, SC) was administered daily nephrotoxicity. Acute nephrotoxicity is a hemodynamic
to rats maintained on low sodium diet for 42 days. Some rats change characterized by renal vasoconstriction that is
were treated with a putative NF-B inhibitor, pyrrolidine dithi- dose-related and reversible. On the other hand, chronicocarbamate (PDTC; 100, 200 mg/kg/day, by gavage). The renal
FK506-induced nephrotoxicity is thought to be progres-function, renal histology, renal NF-B–DNA binding activity
sive and irreversible. These changes include tubular atro-and gene expression profile were examined.
Results. FK506 caused a decline in glomerular filtration and phy, afferent arteriolar hyalinosis and striped interstitial
induced characteristic renal morphologic changes including ar- fibrosis with mononuclear cell infiltration. The precise
teriolopathy, tubular atrophy and interstitial fibrosis. FK506 mechanisms of FK506-induced nephrotoxicity are notmarkedly activated renal cortical NF-B–DNA binding. PDTC
completely understood.administration inhibited NF-B–DNA binding activity in a
In cyclosporine A (CsA) nephropathy, the inflamma-dose dependent manner. With higher dose, NF-B–DNA bind-
ing activity was decreased to a control level. PDTC had little tion accompanied with macrophage infiltration precedes
effect on FK506-induced renal dysfunction. Renal cortical mono- interstitial fibrosis [1, 2]. Precedence of such inflamma-
cyte/macrophage infiltration observed in FK506-treated rats tory responses leads to the development of various typeswas dramatically suppressed by PDTC. FK506 up-regulated
of tubulointerstitial diseases [3–5]. Furthermore, suchrenal cortical gene expression of chemoattractant proteins,
inflammatory cells are a known source of several fibro-monocyte chemoattractant protein-1 (MCP-1) and osteopon-
tin. PDTC significantly blocked MCP-1 gene expression but genic molecules [6].
had no effect on osteopontin gene expression. Tubular atrophy Nuclear factor-B (NF-B) plays a central role in
and tubulointerstitial fibrosis, but not arteriolopathy, were sig- many chronic inflammatory diseases [7] including renalnificantly attenuated by PDTC. FK506 increased renal mRNA
disease [8]. NF-B transcriptionally regulates a varietyexpression of fibrogenic molecules and extracellular matrices
of cellular genes, including pro-inflammatory cytokines,that also were attenuated by PDTC treatment.
Conclusions. NF-B plays an important role in mediating enzymes and adhesion molecules in chronic inflamma-
cortical monocyte/macrophage infiltration and in the pathogen- tory diseases [7]. Among them, monocyte chemoattrac-
tant protein-1 (MCP-1) is a potent macrophage chemo-
attractant [9], the expression of which is regulated by
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NF-B [10]. We previously reported that MCP-1 mRNAinfiltration, tubular injury, interstitial fibrosis, antioxidant, chronic ne-
phropathy, inflammation. expression correlate with monocyte/macrophage infil-
tration in rat model of chronic CsA nephrotoxicity [2].
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stitium and leads to tubulointerstitial fibrosis in chronic pentobarbital (50 mg/kg, IP) and a ventral midline inci-
sion was made. After blood sampling from aorta, bothFK506 nephrotoxicity. The first aim of our study was to
establish whether NF-B is activated in the renal cortex kidneys were perfused with 20 mL cold heparinized sa-
line. Kidneys were immediately excised and the corticesof rats with chronic FK506 nephrotoxicity. The second
aim was to evaluate the effect of NF-B inhibition on were carefully dissected from the medulla, snap frozen
in liquid nitrogen and stored at80C until use for RNAmonocyte/macrophage infiltration, tubular injury and
striped interstitial fibrosis seen in chronic FK506 nephro- extraction. A portion of renal cortical tissue was pro-
cessed for isolation of nuclear protein. The remainingtoxicity.
renal tissues were fixed in 4% paraformaldehyde or
methyl Carnoy’s solution.
METHODS
Animals Functional studies
Plasma and urinary creatinine and electrolytes wereThe present experiments were conducted in accord
with NIH Guide for Care and Use of Laboratory Ani- measured by standard laboratory methods. The whole
blood FK506 level was determined using commerciallymals. All rats and diets were purchased from Clea Japan
(Tokyo, Japan). Adult male Sprague-Dawley rats weigh- available enzyme-linked immunosorbent assay (ELISA)
kit. Blood pressure was measured by tail-cuff method.ing 180 to 200 g at the onset of the experiments were
housed three to a cage and were allowed free access to
Morphologystandard rat chow for three days in a temperature and
light controlled environment. Rats were then housed in Three-micron thick sections of paraformaldehyde-
fixed renal tissue were stained with periodic acid-Shiff’sindividual cages and received a low sodium diet (0.05%
sodium) for a week before FK506 administration. reagent (PAS). Tissue samples were evaluated for tubu-
lar injury, interstitial fibrosis and arteriolopathy by an
Drugs observer masked to the treatment groups.
Tubular injury was scored semiquantitatively for atFK506 and vehicle [mannitol 2.5 mg/mL and HCO60
(polyoxyethylated hydrogenated castor oil) 0.2 mg/mL] least 30 cortical fields (100 magnification) of PAS
stained sample [11]. Tubular injury was defined as tubu-were a gift from Fujisawa Pharmaceutical Co., Ltd.
(Osaka, Japan). FK506 was suspended in its vehicle at lar dilation, atrophy, and thickening of tubular basement
membrane. The following semiquantitative score wasa final concentration of 1 mg/mL. Pyrrolidine dithiocar-
bamate (PDTC; Sigma-Aldrich, Tokyo, Japan) was dis- used: Score 0  no tubular injury; Score 1  10% of
the tubules were injured; Score 2  10 to 25% of thesolved in distilled water to a final concentration of 100
and 200 mg/mL. tubules were injured; Score 3 25 to 50% of the tubules
were injured; Score 4 50 to 75% tubules injured; Score
Experimental groups 5  75% of tubules injured.
Interstitial fibrosis was scored semiquantitatively atDuring the entire experimental period the rats were
maintained on a low sodium diet. Since FK506 treatment least 30 cortical fields (200 magnification) of PAS
stained sample. The following semiquantitative scoredecreased food consumption, pair-feeding was performed
in vehicle-treated rats. Body weight was monitored daily. was used: Score 0  normal interstitium and tubules;
Score 1  mild fibrosis in the tubulointerstitium; ScoreTo examine the effect of NF-B inhibition, rats were
divided into four groups as follows: 2  modest fibrosis with moderate interstitial widening
between tubules; Score 3  severe fibrosis with severe(1) FK506. Rats received a daily SC injection of FK506
(1 mg/kg/day) for 42 days (N  10); interstitial widening between the tubules.
Arteriolopathy was semiquantitatively estimated by(2) FK506  PDTC 100 mg. Rats received a daily SC
injection of FK506 (1 mg/kg/day) for 42 days and re- counting the percentage of juxtaglomerular arterioles
with hyalinosis per total number of juxtaglomerular arte-ceived PDTC 100 mg/kg/day by gavage (N  8);
(3) FK506  PDTC 200 mg. Rats received a daily SC rioles, with a minimum of 60 glomeruli per tissue sample
assessed.injection of FK506 (1 mg/kg/day) for 42 days and received
PDTC 200 mg/kg/day by gavage (N  8); and
Preparation of renal cortex nuclear protein extracts(4) Vehicle. Rats received a daily SC injection of vehi-
cle (1 mL/kg/day) for 42 days (N  10). Nuclear protein extractions were performed as described
previously with minor modification [12]. Briefly, cortex
Experimental protocol tissue from each rat was rapidly suspended in 0.4 mL of
10 mmol/L Hepes, pH 7.9, containing 10 mmol/L KCl,Following the last dosing, rats were housed in individ-
ual metabolic cages for 24-hour urine collection. At the 0.1 mmol/L ethylenediaminetetraacetic acid (EDTA), 0.1
mmol/L ethyleneglycol-bis-(	-aminoethyl ether)-N,N
-end of the study, animals were anesthetized with sodium
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Table 1. Changes in body weight gain, systolic blood pressure, on a Bio-Spin column (Bio-Rad, Richmond, CA, USA).
plasma creatinine, creatinine clearance and trough FK506
The nuclear protein samples (5 g of protein) were incu-concentration in different experimental groups
bated with 32P-labeled consensus oligonucleotide for 20
Parameters Treatment minutes at room temperature in 20 mmol/L Hepes, pH
Body weight gain g FK506 1258a 7.9, 0.3 mmol/L EDTA, 0.2 mmol/L EGTA, 80 mmol/L
FP100 5118ab
NaCl, 1 mmol/L DTT, 0.2 mmol/L PMSF, 6% glycerolFP200 198abc
VH 1786 and 2 g of poly[dI-dC]. The DNA-protein complexes
Systolic blood pressure FK506 1191 were separated from free DNA probe by electrophoresis
mm Hg FP100 1221
on 6% nondenaturing acrylamide gels in 6.7 mmol/LFP200 1191
VH 1251 Tris-HCl, pH 7.5, 3.3 mmol/L sodium acetate, 0.1 mmol/L
Plasma creatinine concentration FK506 0.920.06a EDTA and 2.5% glycerol. Gels were run at 200 V in a
mg/dL FP100 0.700.02ab
cold room (4C) for three hours, dried, and contactedFP200 0.870.13a
VH 0.280.01 overnight with imaging plate. Specific band was analyzed
Creatinine clearance mL/min FK506 1.4470.124a with bioimaging analyzer (BAS 2500; Fuji Photo Film
FP100 1.9640.129ab
Co., Tokyo, Japan). To demonstrate the specificity ofFP200 1.7960.204a
VH 2.7490.139 DNA-protein binding, the binding reactions were per-
Creatinine clearance FK506 0.3540.027a formed in the presence of nonlabeled consensus oligonu-
mL/min/100 g body weight FP100 0.5170.027
cleotide competitor. Furthermore, a supershift assay wasFP200 0.5900.069
VH 0.6100.33 carried out using rabbit polyclonal IgG against p50, p52
Trough FK506 concentration in FK506 14.80.5 and p65 (Santa Cruz Technology, Santa Cruz, CA, USA).
blood ng/mL FP100 14.10.6
For the supershift assay, the binding reaction of nuclearFP200 13.61.1
protein with the labeled oligonucleotide was carried outValues are meansSE. Abbreviations are: FP100, FK506 with PDTC (100
mg/kg/day); FP200, FK506 with PDTC (200 mg/kg/day); VH, vehicle. FK506 (N  in the presence of specific antibodies, followed by elec-
10), FP100 (N  8), FP200 (N  8), VH (N  10). trophoresis.aP  0.05 vs. vehicle
bP  0.05 vs. FK506
cP  0.05 vs. FP100 Immunohistochemistry
Three-micron thick sections of renal tissue fixed with
methyl Carnoy’s solution were stained with ED-1 anti-
body by labeled streptavidin-biotin (LSAB) method.tetra-acetic acid (EGTA), 1.5 mmol/L MgCl2, 10 mmol/l
NaF, 1 mmol/l Na3VO4, 1 mmol/L dithiothreitol (DTT), After depraffinization and rehydration, endogenous per-
oxidase activity was quenched by 3% H2O2 for 10 minutes20 mmol/L	-glycerophosphate, 0.5 mmol/L phenylmethyl-
sulfonyl fluoride (PMSF), 60g/mL aprotinin, and 2g/mL and the sections were contacted with 5% fetal calf serum
for 30 minutes. Next, sections were incubated with mouseleupeptin. The suspension was gently homogenized with
Dounce homogenizer and incubated on ice for 15 min- monoclonal antibody to the rat monocyte/macrophage
(ED-1, 1:500 dilution; Serotec, Oxford, UK) for one hourutes. Twenty-five microliters of 10% Nonidet CA630 was
then added and the suspension was vigorously vortex- at room temperature. Biotinylated anti-mouse immuno-
globulin, horseradish peroxidase-conjugated streptavi-mixed for 10 seconds. The nuclear fraction was precipi-
tated by centrifugation at 5000 rpm for 10 minutes at 4C din (Dako LSAB2; Dako Corp., Carpinteria, CA, USA)
were used according to manufacturer’s instructions. Im-and then resuspended in 80 L of 20 mmol/L Hepes, pH
7.9, containing 0.4 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L munoreaction products were developed using 3,3
-diami-
nobenzidene (DAB) as the chromogen. Sections wereEGTA, 1.5 mmol/L MgCl2, 20% glycerol, 10 mmol/L NaF,
1 mmol/L Na3VO4, 0.2 mmol/L DTT, 20 mmol/L 	-glyc- then counterstained with methyl green. Monocyte/mac-
rophage infiltration was quantified by counting the num-erophosphate, 0.5 mmol/L PMSF, 60 g/mL aprotinin
and 2 g/mL leupeptin. The mixture was incubated on ber of ED-1 positive cells in 20 randomly chosen 1.0 
1.0 mm areas of renal cortex.ice for 15 minutes, centrifuged at 15000 rpm at 4C for
10 minutes, and the resulting supernatants were stored
mRNAat 80C until use.
RNA extracted by guanidium thiocyanate-phenol-chlor-
Electrophoretic mobility shift assay oform method as previously reported [11] was used for
Northern blot analysis. Then, 10g total RNA was electro-In this study, the sequence of double-stranded oligonu-
cleotide used for EMSA was as follows: consensus NF-B, phoresed on 1.2% agarose gel containing 2.2 mol/L formal-
dehyde and 0.2 mol/L MOPS (pH 7.0), and transferred5
-AGT TGA GGG GAC TTT CCC AGG C-3
 (Pro-
mega, Madison, WI, USA). This probe was end-labeled to a nylon membrane by using the Turboblotter Rapid
Downward Transfer System (Schleicher & Schuell, Das-with [-32P] adenosine 5
-triphosphate (ATP), using T4
polynucleotide kinase and purified by chromatography sel, Germany). The nucleic acids were crosslinked by ultra-
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Fig. 1. Effects of pyrrolidine dithiocarbamate
(PDTC) treatment on FK506-induced nephro-
pathy. Photomicrographs show the renal cor-
tex of salt-depleted rats given FK506 (A ) and
a combination of FK506 and PDTC (200 mg/
kg/day) (B) for 42 days. FK506 treated rats have
severe tubular injury and striped interstitial
fibrosis (A). The combination of FK506 and
PDTC attenuated tubular injury and interstitial
fibrosis (B) (PAS stain, 100 magnification).
violet irradiation (Stratagene, La Jolla, CA, USA). The increase blood pressure in this model and PDTC did not
affect it.membranes were prehybridized at 68C for an hour with
QuikHyb hybridization solution (Stratagene). The mem- Plasma creatinine in the FK506-treated group was sig-
nificantly higher than that of vehicle group. PDTC atbranes were hybridized at 68C overnight with 32P-dCTP-
labeled cDNA probes, washed, and finally exposed to lower dose slightly but significantly attenuated the FK506-
induced increase in plasma creatinine concentration,imaging plate. The specific bands were analyzed with the
bioimaging analyzer (BAS-2500). For all of the RNA whereas at high dose PDTC was without effects. As PDTC
treatment retarded body weight gain, endogenous creati-samples, density of an individual mRNA band was di-
vided by that of glyceraldehyde 3-phosphate dehydroge- nine clearance (CCr) was calculated per animal and per
nase (GAPDH) mRNA band to correct for the difference body weight basis and were both shown in Table 1. FK506
in RNA loading and/or transfer. significantly decreased CCr. Although PDTC appeared to
The cDNA probes used were rat MCP-1 cDNA and attenuate FK506-induced reduction in CCr, such effects
rat osteopontin cDNA [2]. Other cDNAs used were rat were marginal.
transforming growth factor-	1 (TGF-	1), mouse plas-
Histologic changeminogen activator inhibitor 1 (PAI-1), rat tissue inhibitor
of metalloproteinase inhibitor 1 (TIMP-1), rat 1 (type 1) FK506 treated rats had characteristic morphologic le-
collagen, mouse 1 (type IV) collagen and rat GAPDH, sions that were similar to the human chronic nephropa-
all of which have been described previously [11]. thy observed after long-term treatments with CsA and
FK506. Figure 1 shows a typical example of the morphol-
Statistical analysis ogy by microphotography and Figure 2 summarizes the
Data were presented as mean  SE. All data were morphologic data of all groups. FK506 treatment caused
analyzed by using analysis of variance (ANOVA) and a prominent injury consisting of tubular dilation, tubular
individual comparisons were made by using Duncan’s atrophy, sloughing of tubular epithelial cells and thick-
multiple range test. Statistical significance was defined ening of the tubular basement membrane. PDTC dose-
as P  0.05. dependently reduced the degree of tubular injury. Rats
treated with FK506 developed a striped interstitial fi-
brosis that was attenuated also by PDTC. Arteriolopathy
RESULTS of the afferent arteriole was present in FK506-treated
Physiologic study rats but it was not attenuated by PDTC treatment.
Physiologic parameters are summarized in Table 1.
Electrophoretic mobility shift assayThe final body weight gain in FK506 group was lower
than that of vehicle group despite of pair-feeding. Fur- Renal cortical NF-B-DNA binding activity was sig-
nificantly increased by FK506 (Fig. 3). The compositionther, animals treated with PDTC failed to gain as much
weight as those receiving FK506 alone. FK506 did not of FK506-activated NF-B complex consisted predomi-
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Fig. 3. Renal cortical NF-B binding in different groups by electropho-
retic mobility shift assay (EMSA). Abbreviations are in the legend to
Figure 2. (A ) Autoradiogram of EMSA. The bracket indicates specific
NF-B-binding complex. FK506 increased NF-B-DNA binding. Com-
petition assay for NF-B were carried out in the presence of 50-fold
molar excess unlabeled NF-B probe (50) are shown also. Supershift
bands with p50 and p65 antibodies were observed whereas p52 antibody
did not shift the band. (B ) Quantification of the density of each auto-
radiogram. Results are expressed as mean  SE. *P  0.05 vs. vehicle,
†P  0.05 vs. FK506, #P  0.05 vs. FP100.
Fig. 2. Tubular injury, interstitial fibrosis and arteriolopathy in differ-
ent groups at 42 days. Abbreviations are: FP100, FK506 with PDTC (100
PDTC dose-dependently attenuated the FK506-inducedmg/kg/day); FP200, FK506 with PDTC (200 mg/kg/day); VH, vehicle.
Tubular injury, interstitial fibrosis and arteriolopathy were scored semi- increase in NF-B-DNA binding. With a higher dose of
quantitatively as described in the Methods section. Results are ex- PDTC, NF-B-DNA binding activity was decreased topressed as mean  SE. *P  0.05 vs. vehicle, †P  0.05 vs. FK506,
a level not different from that of vehicle-treated rats.#P  0.05 vs. FP100.
Immunohistochemistry
nantly of p50 and p65 subunits of the NF-B protein Monocyte/macrophage infiltration was increased by
family, as determined in supershift assays. The specificity FK506 (Fig. 4). It was predominantly detected in the
of NF-B-DNA binding complex was confirmed by com- widened interstitium around injured tubules. Monocyte/
plete displacement of NF-B-DNA complex in the pres- macrophage influx was dramatically attenuated by PDTC
in a dose-dependent manner. Especially in the PDTC 200ence of 50-fold molar excess unlabeled NF-B probe.
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with calcineurin inhibitors, CsA and FK506. PDTC al-
most completely blocked the FK506-induced increase in
NF-B binding activity and monocyte/macrophage influx.
PDTC also attenuated the FK506-induced tubular injury
and interstitial fibrosis. Thus, NF-B activation could
play an important role in the progression of renal injury
in chronic FK506 nephropathy.
Activation of NF-B transcription factor family plays
a central role in various chronic inflammatory diseases
[7], including renal disease [8], through its ability to in-
duce transcription of proinflammatory genes [13]. The
association of tubulointerstitial inflammation with in-
creased NF-B–DNA binding activity implies a role for
NF-B in the pathogenesis of chronic FK506 nephropa-
thy. Furthermore, PDTC treatment dramatically blocked
the activation of NF-B–DNA binding and interstitial
infiltration of monocyte/macrophage. Both in vivo and
in vitro evidence demonstrate that PDTC is a putative
inhibitor of NF-B [14, 15]. Although the precise mecha-
nism of the effect of PDTC on NF-B sequestrations is
unknown, the present findings support the notion that
NF-B activation is implicated in the FK506-induced
influx of mononuclear cells.Fig. 4. Effects of PDTC treatment on renal cortical infiltration of mono-
Infiltration of mononuclear cells into the cortical inter-cyte/macrophage. Abbreviations are in the legend to Figure 2. Mono-
cyte/macrophage infiltration was evaluated by ED-1 immunostaining. stitium was associated with up-regulation of MCP-1, a
(A ) FK506-treated rats showed a marked influx of ED-1 positive cells potent macrophage chemoattractant [9]. We previouslythat was predominantly detected in widened interstitium around injured
showed an increased expression of MCP-1 in rat modeltubules at day 42. (B ) This influx was nearly abolished with PDTC (200
mg/kg/day; magnification 40). (C ) Semiquantitative scoring analysis of chronic CsA nephrotoxicity [2]. It is well known that
of ED-1 positive cells. Results are expressed as mean  SE. *P  0.05 NF-B plays an important role in the transcriptionalvs. vehicle, †P  0.05 vs. FK506, #P  0.05 vs. FP100.
control of MCP-1 [10]. As anticipated, PDTC attenuated
MCP-1 gene expression, but the effect was partial. Thus,
inhibition of MCP-1 expression alone could not explain
mg treated group, the number of monocyte/macrophage the almost complete blockade of macrophage infiltration
was not different from that observed in vehicle group. by PDTC. It is possible that additional cytokines, en-
zymes or adhesion molecules regulated by NF-B also
mRNA were involved in the FK506-induced macrophage influx.
It should be pointed out that osteopontin is anotherGene expression of MCP-1 and osteopontin was mark-
macrophage chemoattractant [16] that was markedly up-edly enhanced in the FK506 group (Fig. 5). Extracellular
regulated with FK506 treatment. However, PDTC hadmatrices mRNA including collagen I and IV were in-
no effect on osteopontin expression, thus eliminating thecreased also in FK506 treated rats. Profibrogenic gene
role of osteopontin in inducing the macrophage influx inexpressions including TGF-	1, PAI-1 and TIMP-1 mRNA
chronic FK506 nephrotoxicity.were significantly up-regulated in FK506-treated rats.
Inflammatory responses such as monocyte/macrophageAll these increases in gene expression except that of
influx are common features that lead to the developmentosteopontin were significantly attenuated by PDTC.
of various types of tubulointerstitial disease [3–5]. In CsA
nephropathy, the interstitial inflammation accompanied
DISCUSSION by macrophage infiltration preceded interstitial fibrosis
The present study shows that long-term treatment of [1, 2]. Monocyte/macrophage is a known source of sev-
rats with FK506 elicits chronic nephropathy that is asso- eral fibrogenic genes including TGF-	, which is highly
ciated with an increase in renal cortical NF-B–DNA correlated to fibrogenic processes [6]. These notions to-
binding activity. These lesions include arteriolopathy, tu- gether with the present finding that PDTC blocked FK506-
bular injury (tubular dilation, tubular atrophy and thick- induced macrophage influx and attenuated tubular injury
ening of tubular basement membrane), interstitial mono- and tubulointerstitial fibrosis suggest that blockade of
cyte/macrophage influx and striped interstitial fibrosis, mononuclear cell infiltration and inflammation contrib-
uted to the attenuation of FK506-induced renal fibrosiswhich mimics chronic nephropathy seen in patients treated
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Fig. 5. Effects of PDTC treatment on renal cor-
tical mRNA in FK506-treated rats. Abbrevia-
tions are in the legend to Figure 2. Symbols are:
() FK506; ( ) FP100; ( ) FP200; () VH.
Ten micrograms of total RNA was isolated
from cortex and hybridized with cDNA probe
to MCP-1, osteopontin, TGF-	1, collagen I and
IV, PAI-1 and TIMP-1. The ordinate shows
each mRNA values corrected for GAPDH
mRNA values. Results are expressed as mean
SE. *P 0.05 vs. vehicle, †P 0.05 vs. FK506,
#P  0.05 vs. FP100.
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with PDTC treatment. Such a histologic improvement of PDTC. Despite such toxicities, PDTC successfully
blocked the activation of NF-B induced by FK506.was supported by the finding that PDTC attenuated
In summary, the present study clearly shows that inFK506-induced gene expressions of pro-fibrogenic mole-
vivo activation of NF-B plays an important role in thecules such as TGF-	1, PAI-1 and TIMP-1 and extracellu-
progression of chronic FK506 nephropathy. Therefore,lar matrix component, collagens I and IV. TGF-	 directly
clinical study about how chronic FK506 nephrotoxicitystimulates extracellular matrix including collagens I and
blocks NF-B activation may prove worthwhile. FurtherIV [6], and also blocks extracellular matrix degradation
studies are needed to elucidate the role of NF-B inby stimulating protease inhibitor, like PAI-1 and TIMP-1
FK506-induced nephropathy. For this purpose, the local-[17]. Shihab et al showed that TGF-	 is involved in
ization of the activated NF-B proteins should be clari-FK506-induced nephropathy [18].
fied. Such a study should be followed by experimentsIt should be pointed out, however, that an almost
using more specific NF-B inhibitions such as NF-Bcomplete blockade of macrophage influx and NF-B-
decoy oligodeoxynucleotide or dominant negative I-B.DNA binding is in contrast with the partial inhibition
of renal fibrosis and corresponding attenuation of gene
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